Articles related to IMMUNOTHERAPY

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Explore the potential of CARv3-TEAM-E T cells in recurrent glioblastoma, a novel therapy showing promise with rapid tumor regression and no severe adverse effects in early clinical evaluation.

Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.

This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.